BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20160479)

  • 21. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.
    Pang MF; Lin KW; Peh SC
    Cell Mol Biol Lett; 2009; 14(2):222-47. PubMed ID: 19082921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch.
    Pajic A; Polack A; Staege MS; Spitkovsky D; Baier B; Bornkamm GW; Laux G
    J Gen Virol; 2001 Dec; 82(Pt 12):3051-3055. PubMed ID: 11714983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.
    Vockerodt M; Tesch H; Kube D
    Genes Immun; 2001 Dec; 2(8):433-41. PubMed ID: 11781710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of CD44 expression by the Epstein-Barr virus latent membrane protein LMP1 is associated with lymphoma dissemination.
    Walter J; Schirrmacher V; Mosier D
    Int J Cancer; 1995 May; 61(3):363-9. PubMed ID: 7537255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue.
    Bornkamm GW
    Semin Cancer Biol; 2009 Dec; 19(6):351-65. PubMed ID: 19619654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The curious case of the tumour virus: 50 years of Burkitt's lymphoma.
    Thorley-Lawson DA; Allday MJ
    Nat Rev Microbiol; 2008 Dec; 6(12):913-24. PubMed ID: 19008891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus and the somatic hypermutation of immunoglobulin genes in Burkitt's lymphoma cells.
    Harris RS; Croom-Carter DS; Rickinson AB; Neuberger MS
    J Virol; 2001 Nov; 75(21):10488-92. PubMed ID: 11581418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus, the TCL-1 oncogene and Burkitt's lymphoma.
    Bell A; Rickinson AB
    Trends Microbiol; 2003 Nov; 11(11):495-7. PubMed ID: 14607063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of Epstein-Barr virus-gene products in Burkitt's lymphoma in Northeast Brazil.
    Araujo I; Foss HD; Bittencourt A; Hummel M; Demel G; Mendonca N; Herbst H; Stein H
    Blood; 1996 Jun; 87(12):5279-86. PubMed ID: 8652843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of the polyamine regulator spermidine/spermine N(1)-acetyltransferase by Epstein-Barr virus in a Burkitt's lymphoma cell line.
    Shi M; Gan YJ; Davis TO; Scott RS
    Virus Res; 2013 Oct; 177(1):11-21. PubMed ID: 23891576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between Epstein-Barr virus and Burkitt's lymphoma in Taiwan.
    Chao TY; Wang TY; Lee WH
    Cancer; 1997 Jul; 80(1):121-8. PubMed ID: 9210717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma.
    Ruf IK; Rhyne PW; Yang H; Borza CM; Hutt-Fletcher LM; Cleveland JL; Sample JT
    Curr Top Microbiol Immunol; 2001; 258():153-60. PubMed ID: 11443860
    [No Abstract]   [Full Text] [Related]  

  • 33. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
    Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
    J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease.
    Hammerschmidt W; Sugden B
    Trends Mol Med; 2004 Jul; 10(7):331-6. PubMed ID: 15242681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
    Cen O; Kannan K; Huck Sappal J; Yu J; Zhang M; Arikan M; Ucur A; Ustek D; Cen Y; Gordon L; Longnecker R
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers.
    Bornkamm GW
    Int J Cancer; 2009 Apr; 124(8):1745-55. PubMed ID: 19165855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.
    Swart R; Ruf IK; Sample J; Longnecker R
    J Virol; 2000 Nov; 74(22):10838-45. PubMed ID: 11044134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells.
    Rechsteiner MP; Berger C; Weber M; Sigrist JA; Nadal D; Bernasconi M
    J Gen Virol; 2007 May; 88(Pt 5):1454-1459. PubMed ID: 17412973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Epstein-Barr virus in Burkitt's lymphoma.
    Takada K
    Curr Top Microbiol Immunol; 2001; 258():141-51. PubMed ID: 11443859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1.
    Kanai K; Satoh Y; Saiki Y; Ohtani H; Sairenji T
    Virus Genes; 2007 Jan; 34(1):55-61. PubMed ID: 16917741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.